Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ABL1 | P00519 | 1/20 | 0.78 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381261 | 1.00 | LMNA (0.78) | LMNAKDM4EABL1SERPINE1MEN1 | |
| SCHEMBL16769729 | 0.88 | KDM4E (0.76) | LMNAKDM4EABL1SERPINE1MEN1 | |
| SCHEMBL30540328 | 0.88 | LMNA (1.00) | LMNAKDM4EABL1MEN1ALDH1A1 | |
| SCHEMBL31381203 | 0.86 | KDM4E (0.61) | LMNAKDM4EABL1SERPINE1MEN1 | |
| SCHEMBL25111352 | 0.84 | LMNA (0.71) | LMNAKDM4EABL1MEN1ALDH1A1 | |
| SCHEMBL16238716 | 0.84 | KDM4E (0.60) | LMNAKDM4EABL1SERPINE1MEN1 | |
| SCHEMBL16648616 | 0.84 | KDM4E (0.71) | LMNAKDM4EABL1MEN1ALDH1A1 | |
| SCHEMBL2000948 | 0.83 | KDM4E (0.65) | LMNAKDM4EABL1MEN1ALDH1A1 | |
| SCHEMBL30286061 | 0.83 | KDM4E (0.65) | LMNAKDM4EABL1MEN1ALDH1A1 | |
| SCHEMBL26121794 | 0.83 | KDM4E (0.65) | LMNAKDM4EABL1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109731123-A | A kind of medical nursing anti-infective material and preparation method thereof | 湖南博隽生物医药有限公司 | 2019-05-10 | — | — | CN | claimed |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-4553068-A1 | PYRIMIDINE DERIVATIVES | ASKA Pharmaceutical Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-20240174635-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-30 | — | — | US | disclosed |
| WO-2024010015-A1 | PYRIMIDINE DERIVATIVES | あすか製薬株式会社 | 2024-01-11 | — | — | WO | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| US-11807622-B2 | TLR 9 inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-11-07 | — | — | US | disclosed |
| EP-3917920-A1 | TLR INHIBITORS | Insilico Medicine IP Limited (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-113710659-A | TLR inhibitors | 英矽智能科技知识产权有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-1670761-B1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | XENTION LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1670761-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005040119-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | LMNA 2016/4885KDM4E 3923/4885ABL1 1093/4885 |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | LMNA 485/4885KDM4E 715/4885ABL1 1345/4885 |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | PTGES, PTGS1, PTGIS | LMNA 4184/4885KDM4E 3195/4885ABL1 2790/4885 |
| US-11807622-B2 | TLR 9 inhibitors | TLR9, TLR1, TLR7 | LMNA 2378/4885KDM4E 943/4885ABL1 132/4885 |
| US-20240174635-A1 | TLR 9 INHIBITORS | TLR9, TLR1, TLR7 | LMNA 2378/4885KDM4E 943/4885ABL1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.